| 2.25 -0.05 (-2.17%) | 07-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.81 | 1-year : | 3.06 |
| Resists | First : | 2.41 | Second : | 2.61 |
| Pivot price | 2.23 |
|||
| Supports | First : | 2.07 | Second : | 1.73 |
| MAs | MA(5) : | 2.21 |
MA(20) : | 2.25 |
| MA(100) : | 2.95 |
MA(250) : | 7.91 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 48.6 |
D(3) : | 40.8 |
| RSI | RSI(14): 45.4 |
|||
| 52-week | High : | 24.89 | Low : | 2.07 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ INBS ] has closed below upper band by 40.4%. Bollinger Bands are 85.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 95 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.36 - 2.37 | 2.37 - 2.38 |
| Low: | 2.17 - 2.18 | 2.18 - 2.2 |
| Close: | 2.23 - 2.25 | 2.25 - 2.27 |
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Fri, 10 Jul 2026
Intelligent Bio Solutions Company Profile & Introduction - Moomoo
Sat, 04 Jul 2026
Intelligent Bio Solutions(INBS) Stock Options Chain | Quotes & News - Moomoo
Fri, 26 Jun 2026
Enterprise value to EBIT forward of Intelligent Bio Solutions Inc. – NASDAQ:INBS - TradingView
Tue, 16 Jun 2026
Interference study backs Intelligent Bio (NASDAQ: INBS) U.S. codeine test - Stock Titan
Wed, 13 May 2026
INTELLIGENT BIO SOLUTIONS INC. 3Q 2026: Revenue $1.06M, Net loss $(2.86M) — 10-Q Summary - TradingView
Wed, 13 May 2026
Intelligent Bio Solutions Releases Q3 2026 Financial Results - AlphaStreet
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 8.7 (%) |
| Shares Short | 85 (K) |
| Shares Short P.Month | 91 (K) |
| EPS | -11.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.48 |
| Profit Margin | -296.8 % |
| Operating Margin | -277.4 % |
| Return on Assets (ttm) | -57.3 % |
| Return on Equity (ttm) | -170.2 % |
| Qtrly Rev. Growth | 45.5 % |
| Gross Profit (p.s.) | 0.77 |
| Sales Per Share | 1.63 |
| EBITDA (p.s.) | -4.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.2 |
| PEG Ratio | 0 |
| Price to Book value | 0.5 |
| Price to Sales | 1.37 |
| Price to Cash Flow | -0.5 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|